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ABSTRACT
This study evaluated the utilization of a porous coating, derived with electrostatic spray deposition
(ESD), as a carrier material for transforming growth factor-b1 (TGF-b1). A porous b-tricalcium phos-
phate coating was deposited with ESD, and 10 ng of 125 I-labeled TGF-b1 was loaded on the substrates. A
burst release during the first hour of incubation of >90% was observed, in either culture medium or
phosphate-buffered saline (PBS). Ninety-nine percent of the growth factor was released after 10 days of
incubation. All samples were able to inhibit epithelial cell growth, indicating that the growth factor had
remained bioactive after release. Thereafter, osteoblast-like cells were seeded upon substrates with or
without 10 ng of TGF-b1. While proliferation of osteoblast-like cells was increased on TGF-b1-loaded
substrates, differentiation was inhibited or delayed. In conclusion, a porous ESD-derived calcium
phosphate coating can be used as a carrier material for TGF-b1, when a burst release is desired.
INTRODUCTION
GROWTH FACTORS ARE TISSUE-SPECIFIC POLYPEPTIDES, act-ing as local regulators of cellular activity.1 The nat-
ural bone matrix contains many growth factors, including a
number from the transforming growth factor-b (TGF-
b) superfamily. When bone is remodeled or affected by
trauma growth factors are released from the bone matrix,
which influence bone cell metabolism and help to stimulate
natural repair. When treating bone defects it may be de-
sirable to supplement the site of trauma with growth factors
to stimulate bone formation. One of the isoforms often
studied in this respect is TGF-b1, a 25-kDa polypeptide. In
vivo studies have shown the stimulating effects of TGF-b1
on osteogenesis in orthotopic sites.2 During initial healing,
TGF-b1 exerts an immunosuppressive effect, stimulates the
deposition of extracellular matrix, inhibits the formation of
osteoblast-like cells, and is a chemotactic factor for various
cell types, among others, osteoblast-like cells.3,4 On the
other hand, when applied in an ectopic site, TGF-b1 does
not give rise to new bone formation.5 Effects of TGF-b1
in vitro are dependent on cell type and concentration.6,7
Nevertheless, it has to be noted that proliferation of me-
senchymal cell types, such as osteoblast-like cells, is sti-
mulated on exposure to TGF-b1.3
An approach to supply growth factors to the body is by
means of a carrier material. This carrier should be site-
specific and biocompatible, and has 2 functions. First, the
carrier acts as a transport medium, as it is supposed to deliver
the growth factor to the desired site. Second, the carrier
itself can guide the regeneration process.8 In view of this,
calcium phosphate (CaP) ceramics have been extensively
used as carrier materials for growth factors. Recombinant
human (rh)TGF-b1 has been adsorbed onto ceramic coat-
ings,9–11 ceramic discs,12,13 and mixed into paste-like for-
mulations.14–16
Although many studies use CaP ceramics as carrier ma-
terial for inductive factors, every combination of a specific
CaP ceramic and inductive factor has its own specific char-
acteristics. A relatively new technique developed for the
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deposition of CaP coatings is electrostatic spray deposition
(ESD), which is based on the generation of an aerosol con-
taining calcium and phosphate ions. The aerosol is directed
toward a heated substrate. The solvent will evaporate, leaving
a CaP coating on the substrate. The technique has several
benefits over the others currently applied, including the
control over the morphological and chemical properties of
the coating.17 With the ESD technique, for instance, porous
CaP coatings can be deposited. This porosity could enable a
better diffusion of nutrients and efflux of metabolites during
tissue regeneration. Further, the porosity could be beneficial
from a biomaterials aspect for the incorporation of growth
factors and osteogenic cells. To date, growth factor release
from ESD-derived coatings has not yet been described.
We hypothesize that a porous, ESD-derived CaP coating
can serve as a carrier material for TGF-b1. Further, the use
of a TGF-b1-loaded CaP coating will have an effect on the
proliferation of osteoblast-like cells cultured on this coat-
ing. The aims of this study were therefore to determine the
release characteristics of TGF-b1 from a porous CaP
coating that was deposited with ESD, and to determine the
effects on an osteoblast-like cell culture. After deposition,
the coating was fully characterized and loaded with TGF-
b1. TGF-b1 was labeled with radioactive iodine and in-
cubated in medium or phosphate-buffered saline (PBS) for
up to 10 days to determine the release in vitro. In addition,
the activity of the released TGF-b1 was determined in a
bioassay. Further, osteoblast-like cells were seeded upon
these coatings, to examine the effects of TGF-b1. Pro-
liferation, alkaline phosphatase (ALP) activity, and osteo-
calcin expression were evaluated. Finally, cell morphology
was examined via scanning electron microscopy.
MATERIALS AND METHODS
Preparation of the substrates
To obtain a completely smooth substrate surface, silicon
wafers (WaferNet GmbH, Eching, Germany) with a thickness
of 0.5 mm were cut into square substrates (0.80.8 cm).
These silicon substrates were coated with 50 nm thick tita-
nium (Ti) layer using the RF magnetron sputter technique
(Edwards ESM 100), to mimic the surface of a Ti implant.18
The duration of sputtering was 5 min while the substrates
were rotated (the sputter power was 200 W, the process
pressure was 5103 mBar, and the sputter rate 10 nm/min).
Subsequently, substrates were cleaned ultrasonically in iso-
propanol for 5 min.
Thereafter, the ESD technique was used to deposit a 1.0–
1.5 mm thick, porous CaP coating on the substrates.17 The
ESD coating procedure was performed using a vertical ESD
setup (Advanced Surface Technology, Bleiswijk, the Neth-
erlands) with a 2-component nozzle. The precursor solutions
used for the coating were 5.66 mM Ca(NO3)24H2O in bu-
tylcarbitol (C8H18O3) and 3.33 mM H3PO4 in butylcarbitol.
The applied voltage was 6.3–6.5 kV, the flow rate was 1 mL/
h, and the deposition time was 45 min. During the deposi-
tion, substrates were heated to 3508C. The distance between
the nozzle and the substrate was 20 mm.
After deposition, substrates were subjected to an addi-
tional heat treatment for 2 h at 10008C to induce crystal-
linity. Subsequently, substrates were sterilized via
autoclaving for 15 min at 1218C.
Physicochemical analysis
A physicochemical analysis was performed on the sub-
strates. The physicochemical analysis consisted of the fol-
lowing techniques:
 X-ray diffraction (XRD; to assess phase composition
and crystallinity). For XRD, a thin film Philips X-
ray diffractometer was used, using CuKa-radiation
(PW3710, 40 kV, 40 mA).
 Fourier transform infrared spectroscopy (FTIR; to as-
sess molecular composition). The infrared spectra of
the films on the substrates were obtained by reflection
FTIR (PerkinElmer).
 Energy dispersive spectrometry (EDS; to assess Ca /P
ratio). To determine the calcium/phosphate ratio of the
coatings, discs were examined using a Jeol 6310 SEM
which was equipped with an energy disperse X-ray
detector.
 Scanning electron microscopy (SEM; to assess surface
morphology). Discs were sputter-coated with gold and
examined and photographed using a Jeol 6310 SEM.
Recombinant human TGF-b1 release in vitro
Recombinant human (rh)TGF-b1 (R&D Systems, Min-
neapolis, MN) was radioiodinated with 125I according to
the iodogen method.19 Briefly stated, 2 mg rhTGF-b1 was
solubilized in 10 mL of 4 mM HCl, centrifuged (20 s,
2500 rpm), and the content was transferred to an 0.5-mL
Eppendorf vial coated with 50 mg of 1,3,4,6-tetrachloro-
3a,6a-diphenylglucouril (Iodogen) (Pierce, Rockford, IL).
The vial containing latent rhTGF-b1 was rinsed twice with
40 mL of 50 mM phosphate buffer, which was added to the
iodogen vial. To the iodogen vial (¼5 mL) was added 0.7 mCi
Na125I (Amersham Intl., Amersham, UK) and the vial in-
cubated at room temperature for 5 min. One hundred micro-
liters of saturated tyrosine solution was added to the reaction
mixture. The reaction mixture was separated on a disposable
Sephadex G25M column (PD10, Amersham-Pharmacia,
Uppsala, Sweden) and was eluted with PBS–0.1% BSA. The
void fractions containing 125I-TGF-b1 were pooled fraction.
The specific activity of the 125I-TGF-b1 was 200 mCi/mg.
The radiochemical purity was determined by instant thin-
layer chromatography (ITLC) and exceeded 95%.
Ten nanograms of the 125I-labeled rhTGF-b1 was loaded
on the coatings (n¼ 3 for all samples). For this, a 10-mL
droplet of PBS–BSA 0.1% containing 10 ng of rhTGF-b1
was placed on the coatings, and distributed over the entire
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surface area. After the droplets solution was placed on the
coatings, substrates were frozen at –208C and lyophilized
overnight to dehydrate the substrates. Subsequently, the
substrates were placed in glass vials containing either 5 mL of
osteoblast culture medium (a-minimal essential medium (a-
MEM), supplemented with 10% fetal calf serum (FCS; Gibco
BRL, Life Technologies B.V. Breda, the Netherlands), 50mg/
mL of ascorbic acid (Sigma-Aldrich, St. Louis, MO), 50mg/
mL of gentamicin, 10 mM Na-b-glycerophosphate (Sigma-
Aldrich), and 108 M dexamethasone (Sigma-Aldrich), or
5 mL of PBS, and incubated at 378C. After 1, 4, 24, 72, and
240 h of incubation, substrates were transferred to a fresh
glass vial containing 5 mL of culture medium or 5 mL of PBS.
The radioactivity of the old vials (with remaining culture
medium–PBS) as well as the fresh vials (culture medium/
PBS with substrate) was counted with a gamma counter (1480
Wizard 3@, PerkinElmer Life Sciences, Boston, MA). Both
release and retention were calculated independently: the re-
tention was measured as percentage of the originally loaded
rhTGF-b1. The release was measured as the accumulated
percentage of the originally loaded rhTGF-b1.
TGF-b1 activity after release
Substrates were loaded with 10 ng of TGF-b1 as described
in the preceding text, albeit unlabeled (n¼ 2). To test whether
released TGF-b1 was still bioactive, a mink lung epithelial
(MLE) cell test was used, as MLE cells show drastic in-
hibition of proliferation after exposure to bioactive TFG-b1.
First, substrates were placed in a vial containing 2 mL of a-
MEM supplemented with 10% FCS and 50mg/mL of gen-
tamicin. Then substrates were incubated at 378C, 5% carbon
dioxide(CO2), and 95% humidity. After 72 h, culture medium
was removed and added to a population of MLE cells (cell
line CCL-64, Mv-1-Lu, ATCC, Manassas, VA) seeded in a
24-well plate at a density of 56,000 cells/cm2. The cells were
incubated at 378C, 5% CO2, and 95% humidity.
After 3 days of culture, the DNA content of every well
was examined. Culture medium was removed from the cell
layer. Cells were washed twice with PBS and subjected to 2
freezing–defrosting cycles in 1 mL of deionized water.
Subsequently, the total amount of DNA was measured using
a PicoGreen dsDNA Quantitation Kit (Molecular Probes,
Eugene, OR), according to the instructions of the manu-
facturer. Briefly stated, dsDNA stock was used to generate
a standard curve ranging from 0 to 2000 ng/mL. A 100-mL
sample and 100 mL of PicoGreen working solution were
added to the wells of a 96-well plate. The plate was in-
cubated at room temperature in the dark for 2 to 5 min.
Thereafter, the plate was read at 480–520 nm. With the aid
of the standard curve, DNA content could be determined.
Samples and standards were assayed in duplicate.
Osteoblast-like cell isolation and culture
Rat bone marrow cells were obtained from the femora of
1 male, 40–43-day old Wistar WU rat per culture run. Both
femora were removed and washed 3 times with a-MEM
supplemented with 0.5 mg/mL of gentamicin and 3 mg/mL
of fungizone (Gibco). Subsequently, the epiphyses were cut
off and diaphyses were flushed out with osteoblast culture
medium to remove the bone marrow. The bone marrow was
divided over 3 culture flasks (75 cm2) and cultured in os-
teoblast culture medium. The cells were incubated at 378C,
5% CO2, and 95% humidity. The following day, culture
medium was refreshed to remove all nonadherent cells.
After this, culture medium was refreshed every 2–3 days.
After 7 days of primary culture, cells were detached
using trypsin–EDTA (0.25% w/v trypsin–0.02% EDTA).
The cells were concentrated, resuspended in 10 mL of
culture medium, and counted using a Coulter Counter. For
seeding, 11,500 cells/cm2 were added to either the sub-
strates with 10 ng of TGF-b1, or to nonloaded control
substrates. Substrates with adherent cells were incubated at
378C, 5% CO2, and 95% humidity. Medium was refreshed
every 2–3 days.
Proliferation
After 1, 4, 8, and 12 days of cell culture, proliferation of
the cells was examined by determining the DNA content of
every substrate (n ¼ 4). Culture medium was removed from
the cell layer. Subsequently, total DNA was collected and
measured using a PicoGreen dsDNA Quantitation Kit, as
described earlier. Samples and standards were assayed in
duplicate.
ALP activity assay
After DNA analysis, the same samples were used to
determine ALP activity. 4-Nitrophenol (4-NP) stock was
diluted in buffer solution (5 mM MgCl2, 0.5 M 2-amino-2-
methyl-1-propanol), to generate a standard curve ranging
from 0 to 25 nM. A 80-mL sample and 20 mL of buf-
fer solution were added to the wells of a 96-well plate.
Subsequently, 100 mL of substrate solution (5 mM para-
nitrophenylphosphate) was added to the wells, and the plate
was incubated at 378C for 1 h. The reaction was stopped by
adding 100 mL of 0.3 M NaOH. Finally, the plate was read
via an enzyme-linked immunosorbent assay (ELISA)
reader at 405 nm. With the aid of the standard curve, ALP
activity was determined in nM 4-NP produced per hour per
nanogram of DNA. Samples and standards were assayed in
duplicate.
Osteocalcin content
The osteocalcin content was measured with an enzyme
immunoassay (EIA; Biomedical Technologies, Stoughton,
MA). After 8, 16, and 24 days of culture, cell layers were
washed twice with PBS, scraped off in 1 mL of EIA sample
buffer, and stored at –208C until use (n¼ 3).
For analysis, osteocalcin stock was diluted in sample
buffer to generate standards ranging from 0 to 40 ng/mL. A
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100-mL sample was added to the wells of a 96-well plate,
and the plate was incubated at 48C for 24 h. Hereafter, the
wells were washed 3 times with wash buffer. One hundred
microliters of osteocalcin antiserum was added, and the
plate was incubated at 378C for 1 h. Subsequently, the wells
were washed 3 times with wash buffer. One hundred mi-
croliters of donkey anti-goat IgG peroxidase was added,
and the plate was incubated at room temperature for 1 h.
The wells were washed 3 times with wash buffer. One
hundred microliters of substrate mix was added, and the
plate was incubated at room temperature in the dark for
30 min. One hundred microliters of stop solution was ad-
ded, and absorbance was read with an ELISA reader at
450 nm. With the aid of the standard curve, total osteo-
calcin content could be determined. Samples and standards
were assayed in duplicate.
SEM
After 1, 4, 8, and 16 days of culture, substrates (n¼ 2)
were washed twice with PBS. Cells were fixed for 5 min in
2% glutaraldehyde. Subsequently, substrates were washed
for 5 min with 0.1 M sodium-cacodylate buffer (pH 7.4),
dehydrated in a graded series of ethanol, and dried with
tetramethylsilane. The substrates were sputter-coated with
gold and examined via a Jeol 6310 SEM.
Statistical analysis
The complete experiment was performed in duplicate
to ensure reproducibility. Further, every sample was mea-
sured in duplicate. Statistical analysis was performed us-
ing an unpaired t-test. Calculations were performed
in GraphPad InStat, Version 3 (GraphPad Software, San
Diego, CA).
RESULTS
Physicochemical analysis
XRD and FTIR spectrometry showed that after the heat
treatment, the CaP coating was a crystalline b-tricalcium
phosphate (b-TCP) coating. ESD analysis showed a cal-
cium over phosphate ratio of 1.4–1.5. SEM revealed that
the CaP coating had a porous surface structure (Fig. 1).
rhTGF-b1 release in vitro
Figure 2 shows the release characteristics of 125I-labeled
rhTGF-b1 in culture medium and PBS. After 1 h of in-
cubation, the 10 ng-loaded coatings had released 95.3% of
their rhTGF-b1 content into the culture medium. This in-
creased in time up to 99.4% after 10 days. Similar results
were found for samples placed in PBS. After 1 h, a release of
95.5% was observed, which increased to 99.6% after 10 days
of incubation. As mentioned, the retention was also mea-
sured. The retention added to the release was always 100%.
TGF-b1 activity after release
Substrates that were loaded with 10 ng of TGF-b1 were
placed in culture medium for 3 days. This medium was
removed and added to a culture of MLE cells. The control
group received normal culture medium. Figure 3 shows the
DNA content of MLE cells after 3 days of culture in
medium containing released TGF-b1 or normal culture me-
dium. Compared to the control group, growth of the MLE
cells was significantly inhibited ( p< 0.001) when cultured
in medium with released TGF-b1, which proved that the
released TGF-b1 was still bioactive.
Proliferation of osteoblast-like cells
The results of the proliferation assay from the 2 per-
formed runs with osteoblast-like cells were similar. Results
from the first run are depicted in Fig. 4. DNA content was
measured after 1, 4, 8, and 12 days of incubation. An in-
crease in DNA content is seen in time for both groups.
FIG. 1. Scanning electron micrograph of the porous CaP
coating before cell culture.
FIG. 2. Release profiles of TGF-b1 in culture medium and
PBS in vitro. Ten nanograms pf 125 I-labeled TGF-b1 was loaded
on the substrates. A burst release is seen, followed by a slow
release up to the 240 h time point.
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After 1 and 4 days of incubation, no differences were seen
between cells cultured on substrates with or without TGF-
b1. However, proliferation was markedly stimulated after 8
and 12 days of incubation on the substrates loaded with
TGF-b1, compared to the substrates without TGF-b1.
ALP activity assay
Again, the results of the 2 performed runs were similar,
and the results of the first run are shown in Fig. 5. After 1,
4, and 8 days of culture, no differences were found between
cells cultured on loaded and unloaded substrates. After 12
days of culture, ALP activity is increased for cells cultured
on unloaded substrates, compared to cells cultured on sub-
strates loaded with 10 ng of TGF-b1.
Osteocalcin content
The osteocalcin content for both runs were similar and
the results of run 1 are shown in Fig. 6. No osteocalcin
content could be identified after 8 days for cells cultured on
substrates with or without TGF-b1. After 16 and 24 days of
culture, still no osteocalcin content was observed for cells
cultured on substrates loaded with TGF-b1. In contrast,
osteocalcin content was detected for cells cultured on
substrates without TGF-b1.
SEM
SEM observations revealed no differences between loaded
and unloaded substrates after 1 and 4 days of culture. After 8
days of culture, a confluent cell layer covered the entire sur-
face in both groups. However, cells cultured on substrates
without TGF-b1 showed the beginning of the formation of a
mineralized extracellular matrix. Cells cultured on substrates
loaded with TGF-b1 did not show signs of mineralization.
After 16 days of culture, the difference in the extent of mi-
neralization was more pronounced. Cells cultured on sub-
strates without TGF-b1 showed many mineralized nodules
(Fig. 7A). Cells cultured on substrates with 10 ng TGF-b1 did
not show any signs of mineralization (Fig. 7B). Cross-sections
of the samples presented in Fig. 7A and B are shown in Fig.
7C and D, respectively. Visible are the silicon substrate, the
coating, and the cell layer on top of the coating. In Fig. 7C, the
mineralized matrix is visible. In Fig. 7D, a confluent cell layer
is present on top of the coating.
DISCUSSION
A CaP coating applied on a titanium implant provides the
metal with an osteoconductive layer. In addition to in-
creasing osteoconductive properties, osteoinductive agents,
FIG. 3. The DNA content of MLE a cell culture after 3 days, in
normal culture medium, or medium containing released TGF-b1.
Note the inhibition of growth induced by TGF-b1. Values re-
present the means SD. ***p< 0.001.
FIG. 4. DNA content of osteoblast-like cells cultured on sub-
strates with and without 10 ng of TGF-b1. Values represent the
means SD. *p< 0.05; ***p< 0.001.
FIG. 5. ALP activity of osteoblast-like cells cultured on sub-
strates with and without 10 ng of TGF-b1. Values represent the
means SD. ***p< 0.001.
FIG. 6. Osteocalcin content of osteoblast-like cells cultured on
substrates with and without 10 ng of TGF-b1. Values represent
means SD. **p< 0.01, ***p< 0.001. Color images available
online at www.liebertpub.com/ten.
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such as TGF-b1, can also be applied to a coating to enhance
bone formation. This study examined the utilization of a
porous ESD-derived CaP coating as carrier material for
TGF-b1. Results show a burst-release of bioactive TGF-b1
from the coatings already during the first hour of incuba-
tion. When osteoblast-like cells were seeded on substrates
loaded with TGF-b1, their proliferation was stimulated and
differentiation was inhibited, or delayed. Therefore, results
show that ESD coatings can be carriers for the growth
factor, if a burst release is desired.
Appropriate methods to analyze the parameters of in-
terest had to be selected before commencing this study. To
measure the release of TGF-b1, literature describes the use
of ELISAs,2,20 as well as radioactively labeled growth
factors.9,16,21 In a preliminary study, the release of TGF-b1
was determined via both methods. However, it was found
that data obtained from the ELISAs were largely variable,
whereas data from the radiolabeling study were consistent.
Another major benefit of the use of radioiodinated TGF-b1
over ELISAs was that, in addition to the release, the re-
tention of TGF-b1 in the coating could also be determined.
Therefore, we have selected radioactive labeling as the
preferred technique in this study.
Another technical decision involved the conditions of the
release, as the release can be determined under static or dy-
namic conditions. In the body, release of a growth factor such
as TGF-b1 from a carrier will take place under the dynamic
conditions of tissue and fluid movements. Further, macro-
phages and osteoclasts can remodel and degrade the coating,
thereby influencing the release of TGF-b1. As currently no
tissue culture method is available that accurately mimics such
effects, it was decided to determine the release under static
conditions, which seemed also the most logical choice in
relation to the subsequent cell culture experiment. This dis-
crepancy between in vitro and physiological in vivo condi-
tions can also be the reason that in vivo results do not always
match the in vitro data and that less activity of growth factors
is seen in vivo compared with in vitro studies.
For the in vitro release characteristics, CaP coatings were
loaded with 10 ng of 125I-labeled TGF-b1, and release was
determined in culture medium and PBS. These release media
were chosen as many researchers use a buffered solution
to measure the release. However, to identify the effects of
proteins and ions, release was also determined in culture
medium. Preliminary studies already confirmed that an in-
crease of the dose results in the same kind of burst release,
which is a valid method to increase the final concentration
close to the implant. Regarding literature, it is difficult to
compare the results of the present study, as many experi-
mental parameters are involved, which can all influence the
outcome of the release studies, like the growth factor used,
the method employed to load the carrier material (e.g.,
incorporation or adsorption), type of carrier material (e.g.,
ceramic coating or cement), release media (e.g. serum,
culture medium, or PBS), and techniques to measure the
release (e.g., ELISA or radioactive labeling). A study by
FIG. 7. Scanning electron micrographs of osteoblast-like cells cultured for 16 days. (A) Substrate without TGF-b1. Note the
formation of a mineralized extracellular matrix. (B) Substrate with 10 ng of TGF-b1. Note that mineralization has not occurred. (C, D)
Cross-sections of the samples shown in A and B, respectively. Visible are the silicon substrate, coating, and cell layer. In C, mineralized
matrix is visible (arrow). In D, a thick confluent cell layer is present.
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Ruhe´ et al. confirmed already that release characteristics are
dependent upon the carrier composition and nanostructure as
well as the pH of the release medium.22 On the other hand,
studies with lyophilized growth factors consistently show
burst-release profiles, although the intensity of the burst
release is influenced by the carrier composition. For in-
stance, a burst release of 70% was observed when TGF-b1
was lyophilized on Ti-fiber mesh implants,2 while a 50%
burst release occurred when lyophilizing TGF-b1 on a por-
ous poly(propylene fumarate) scaffold.23 Further, Lind et al.
found an 80% release of TGF-b1 when adsorbed to a plasma
sprayed TCP coating.9 Incorporation of a growth factor into
a bulk material generally leads to no, or a very low release.
Blom et al. found releases of 20%15 and 1%14,20 of TGF-b1
incorporated in CaP cement. Release in such a situation can
be accomplished only after degradation of the carrier ma-
terial. We have to emphasize that literature is not conclusive
on the preferred release profile for growth factors to promote
bone healing. Both systems for sustained as well as burst
release have resulted in success. For instance, bone forma-
tion was stimulated with a sustained release of bone mor-
phogenetic protein-2 (BMP-2) from a porous CaP cement,24
and from poly-L-lactic glycolic acid microspheres in so-
dium carboxymethylcellulose.25 In contrast, bone formation
was also stimulated following a burst release of TGF-b1
from a titanium fiber mesh.24 One recent study described a
comparison between burst and sustained release of the os-
teoinductive protein TP508 in a rabbit radial defect model.
There it was shown that a large burst release of TP508 in-
duced more bone formation.26 Overall, it can be said that the
release profile of every combination of growth factor and
carrier material has to be tailored to comply with the desired
release profile for the effects of a specific growth factor and
the site of implantation. Future studies have to elucidate
whether growth factor components can also be incorporated
in ESD-derived coatings to create a slow release carrier or an
optimized combination of both release profiles.
The osteoblast-like cell assay revealed an increase in
proliferation as well as a decrease in ALP activity and os-
teocalcin levels, on all TGF-b1-loaded substrates. This cor-
roborates with several other studies, which also demonstrated
a similar increase in cell proliferation.27,28 However, litera-
ture data on the effect of TGF-b1 on ALP activity are
somewhat diverse. Centrella et al. reported a decrease in ALP
activity,29 and Harris et al. found a decrease in gene ex-
pression coding for ALP.30 On the other hand, Blom et al.
observed no influence on ALP activity at all,15 whereas an
increase in ALP activity was described by others.27,28 Similar
discrepancies are observed for osteocalcin levels. Still, in
accordance with the present results, most available literature
reports a reduced osteocalcin content after addition of TGF-
b1 during cell culture,12,28 and a decreased gene expression
for osteocalcin.30 A contradictory observation was, for ex-
ample, done by Lu et al., who found an enhanced osteocalcin
production after 21 days.27 Differences in cellular behavior
can possibly be explained by the cell type used. It is known
that cells with the osteoblastic phenotype can have different
responses to TGF-b1. In the ROS 17/2.8, UMR-106, and
MG-63 cell lines TGF-b1 inhibits cell replication and sti-
mulates ALP activity,7 while in the MC3T3, and SaOS-II cell
line, and freshly isolated calvarial cells TGF-b1 increases
cell replication and decreases ALP activity.7 Further, a
concentration-related effect of TGF-b1 can elicit different
responses from the cultured cells. For example, in one of our
previous pilot studies, loading of 5 ng of TGF-b1 upon the
porous ESD-derived CaP coating induced no effect at all on
osteoblast-like cells cultured on the substrates (data not
shown). In addition, Centrella et al. observed that in sparse
cultures of osteoblast-enriched cells, 0.15 ng/mL of TGF-b1
stimulated proliferation, while higher doses gave an in-
hibitory effect. In subconfluent cultures, the peak response
was at 15 ng/mL of TGF-b1.29 Therefore, we can conclude
that the number of cells proportionally to the concentration
TGF-b1 is determining the final cellular response.
CONCLUSIONS
In conclusion, the presented data verify that a porous
ESD-derived CaP coating can be used as a carrier material
for TGF-b1 when a burst release is desired. As confirmed
by the mink lung epithelial cell assay, the released TGF-b1
is still bioactive. In addition, the released TGF-b1 stimu-
lated the proliferation of osteoblast-like cells, while dif-
ferentiation was inhibited or delayed. Future in vivo studies
have to prove the final clinical efficacy of porous ESD-
derived coatings as a carrier material for bone regeneration
supporting growth factors.
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